Regulatory Engagement in a Pre-competitive Partnership to Advance Drug Development Tools for Familial Frontotemporal Degeneration (f-FTD)

Time: 2:30 pm
day: Day One


  • Developing a Context of Use and laying out the evidentiary criteria to support  final tool utility
  • Framing the Letter of Intent (LOI) and expectations along with the Biomarker Qualification Process
  • Case study of Neurofilament of Neurodegeneration in Familial Frontotemporal Degeneration (f-FTD) Informing Amyotrophic Lateral Sclerosis